M.D., Board of Directors, GRAIL; Founder/Director, Juno Therapeutics
Dr. Klausner is founder and Director of Juno Therapeutics, founder and Director of GRAIL and Executive Chairman of Wisdo, a third generation internet company. He is the chairman of Mindstrong and a Director of AnchorDx. He is the former Senior Vice President, Chief Medical Officer and Chief Opportunity Officer of Illumina Corporation. He is the former Executive Chairman of Audax Health. He currently Chairs the Grand Challenges in Cancer program of Cancer Research UK. Previously, he has served as managing partner of the Venture Capital firm, The Column Group, was the Executive Director for Global Health of the Bill and Melinda Gates Foundation. Dr Klausner was appointed by Presidents Clinton and Bush as the eleventh Director of the U.S. National Cancer Institute between 1995 and 2001. Dr. Klausner served as chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health and Human Development as well as a past president of the American Society of Clinical Investigation. He has served in senior advisory roles to the US, Norwegian, Qatari and Indian governments. He previously chaired the International Advisory Board for Samsung and chaired the Strategic Oversight Council of Sanofi. He currently serves on numerous advisory boards. Dr. Klausner is well known for his work in cell and molecular biology, immunology and human genetics, and has been the author of more than 300 scientific articles and several books, in addition to receiving numerous awards, honorary degrees and other honors. He has served as an Advisor to the Presidents of the Academies for counter-terrorism, and Liaison to the White House Office of Science & Technology Policy. He oversaw the writing of The National Science Education Standards, the first such standards for US Science Education. He is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.
Session Synopsis: Many precision medicine initiatives at medical centers, foundations, and providers are aggregating vast amounts of medical data. What are the challenges of creating a universal approach to data sharing versus private and/or proprietary approaches that are trying to differentiate themselves? How do we accumulate and share data effectively without interfering in patient rights? Speakers will cover these questions and more.